Gilead Sciences, Inc. (GILD) Shares Bought by Greenwood Capital Associates LLC
Greenwood Capital Associates LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,170 shares of the biopharmaceutical company’s stock after buying an additional 1,126 shares during the period. Greenwood Capital Associates LLC’s holdings in Gilead Sciences were worth $1,777,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Edge Wealth Management LLC raised its position in shares of Gilead Sciences by 163.1% in the first quarter. Edge Wealth Management LLC now owns 143,394 shares of the biopharmaceutical company’s stock valued at $9,746,000 after buying an additional 88,899 shares during the period. Banced Corp raised its position in shares of Gilead Sciences by 1.6% in the first quarter. Banced Corp now owns 8,792 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 137 shares during the period. Horan Capital Management raised its position in shares of Gilead Sciences by 37.6% in the first quarter. Horan Capital Management now owns 251,000 shares of the biopharmaceutical company’s stock valued at $17,047,000 after buying an additional 68,600 shares during the period. TNB Financial purchased a new position in shares of Gilead Sciences during the first quarter valued at $4,294,000. Finally, Capstone Asset Management Co. raised its position in shares of Gilead Sciences by 6.5% in the first quarter. Capstone Asset Management Co. now owns 214,956 shares of the biopharmaceutical company’s stock valued at $14,600,000 after buying an additional 13,100 shares during the period. 74.04% of the stock is owned by institutional investors.
Gilead Sciences, Inc. (NASDAQ GILD) traded up 2.296% on Thursday, hitting $83.095. The stock had a trading volume of 16,490,457 shares. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $84.13. The firm has a market cap of $108.52 billion, a price-to-earnings ratio of 9.025 and a beta of 1.21. The company’s 50 day moving average price is $72.97 and its 200 day moving average price is $68.87. Gilead Sciences also was the recipient of unusually large options trading activity on Monday. Traders acquired 19,878 put options on the company. This represents an increase of 209% compared to the average volume of 6,434 put options.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.08 earnings per share. Analysts expect that Gilead Sciences, Inc. will post $8.73 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. Gilead Sciences’s payout ratio is presently 22.58%.
Several equities analysts have weighed in on the company. William Blair assumed coverage on Gilead Sciences in a report on Thursday. They set an “outperform” rating and a $87.00 price objective for the company. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Thursday. Berenberg Bank set a $86.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Tuesday. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Monday. Finally, Robert W. Baird reissued an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $81.07.
In related news, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at $242,749,648.34. The disclosure for this sale can be found here. Insiders have sold 206,666 shares of company stock worth $15,223,184 over the last 90 days. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.